Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A rare, genetic, neurological disorder characterized by the association of slowly progressive spinocerebellar degeneration and corneal dystrophy, manifesting with bilateral corneal opacities (which lead to severe visual impairment), mild intellectual disability, ataxia, gait disturbances, and tremor. Additional manifestations include facial dysmorphism (i.e. triangular face, ptosis, low-set, posteriorly angulated ears, and micrognathia), as well as mild upper motor neuron involvement with hypertonia, lower limb hyperreflexia and extensor plantar responses. There have been no further descriptions in the literature since 1985.
Features include common findings: Clouding of the cornea (corneal dystrophy), Ataxia, Spinocerebellar tract degeneration, and Visual impairment and others. 13 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Eyes | 5 | Opacification of the corneal stroma, Corneal stromal edema, Clouding of the cornea (corneal dystrophy) |
Biomarker and diagnostic research for corneal-cerebellar syndrome has been reported in the published literature.
Phenotype severity distribution: 9 common features.
Estimated prevalence: <1 in 1,000,000 (VERY_RARE).
No clinical trials have been registered for corneal-cerebellar syndrome.
300 publications have been identified in PubMed for corneal-cerebellar syndrome. Kisho has analyzed 112 by research type. Research spans Review / Meta-Analysis (70%), Basic Science / Preclinical (14%), and Epidemiology / Natural History (5%).
Research Type | Count | % of Total |
|---|---|---|
Research summaries | 78 | 70% |
Data assembled from 5 of 12 sources · Last updated Sep 18, 2026, 10:24 PM UTC
Online Mendelian Inheritance in Man
European rare disease database
Genetic and Rare Diseases Info Center
Brain and nerves
4 |
Ataxia, Intellectual disability, Progressive cerebellar ataxia |
Laboratory research
16 |
14% |
Disease patterns and progression | 6 | 5% |
Patient case studies | 5 | 4% |
Testing and diagnosis research | 4 | 4% |
Other research | 2 | 2% |
Clinical study results | 1 | 1% |
Manto M (2026). [PMID: 41663552](https://pubmed.ncbi.nlm.nih.gov/41663552/). *J Neurol*. [Review / Meta-Analysis]
Mountford R (2026). [PMID: 41637667](https://pubmed.ncbi.nlm.nih.gov/41637667/). *Eur J Pain*. [Review / Meta-Analysis]
Anderson EN (2026). [PMID: 41468891](https://pubmed.ncbi.nlm.nih.gov/41468891/). *Am J Hum Genet*. [Basic Science / Preclinical]
Papazachariou A (2026). [PMID: 41128447](https://pubmed.ncbi.nlm.nih.gov/41128447/). *Current opinion in clinical nutrition and metabolic care*. [Review / Meta-Analysis]
Amado C (2026). [PMID: 40975490](https://pubmed.ncbi.nlm.nih.gov/40975490/). *Ann Allergy Asthma Immunol*. [Review / Meta-Analysis]
Shabshin G (2025). [PMID: 40261331](https://pubmed.ncbi.nlm.nih.gov/40261331/). *Orthopadie (Heidelberg, Germany)*. [Review / Meta-Analysis]
Aloufi M (2025). [PMID: 40366776](https://pubmed.ncbi.nlm.nih.gov/40366776/). *Orbit*. [Review / Meta-Analysis]
Dotan A (2025). [PMID: 39931017](https://pubmed.ncbi.nlm.nih.gov/39931017/). *Harefuah*. [Review / Meta-Analysis]
Sahoo SS (2025). [PMID: 39475954](https://pubmed.ncbi.nlm.nih.gov/39475954/). *Blood*. [Review / Meta-Analysis]
Yacoub MR (2025). [PMID: 40747632](https://pubmed.ncbi.nlm.nih.gov/40747632/). *Current opinion in allergy and clinical immunology*. [Review / Meta-Analysis]